April 6, 2022Cardiology in the Young

Statistically significant improvements were observed after the initiation of selexipag in terms of mean pulmonary arterial pressure (p < 0.01), pulmonary vascular resistance index (p < 0.05), and cardiac index (p < 0.01).

View Full Paper

Ask AI

Bookmark

Why the study?

The study aimed to investigate the safety, tolerability, and efficacy of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.

Does selexipag improve hemodynamic parameters and have a favorable safety profile in children and young adults with idiopathic and heritable pulmonary arterial hypertension?

Population

11 patients (five children and six young adults) with idiopathic and heritable pulmonary arterial hypertension

Comparison

Selexipag as add-on therapy or transition from beraprost sodium or epoprostenol

Design

Retrospective cohort study

Authors

STShinichi Takatsuki TNTomotaka Nakayama YSYurika Shimizu

Discussion

Member takes

Overview

May support hemodynamic benefit of selexipag in pediatric PAH; hypothesis-generating and requires prospective trials before practice change.

Structured PICO

Does selexipag improve hemodynamic parameters and have a favorable safety profile in children and young adults with idiopathic and heritable pulmonary arterial hypertension?

Population

11 patients (5 children and 6 young adults) with idiopathic and heritable pulmonary arterial hypertension

Intervention

Selexipag as add-on therapy or as a transition from beraprost sodium or epoprostenol infusion therapy (median maintenance dose in children 80 μg/kg/day)

Outcome

Improvement in clinical variables from baseline, including hemodynamic parameters (mean pulmonary arterial pressure, pulmonary vascular resistance index, and cardiac index)surrogate

Selexipag demonstrated potential efficacy in improving hemodynamic parameters and a favorable safety profile in a small cohort of children and young adults with pulmonary arterial hypertension.

Cite This Study

Takatsuki et al. (2022) studied this question.

synapsesocial.com/papers/6a1ce2075b2142ad731dd301 https://doi.org/10.1017/s1047951122000415

View Full Paper

Ask AI

Bookmark

April 6, 2022Cardiology in the Young

Statistically significant improvements were observed after the initiation of selexipag in terms of mean pulmonary arterial pressure (p < 0.01), pulmonary vascular resistance index (p < 0.05), and cardiac index (p < 0.01).

View Full Paper

Ask AI

Bookmark

Why the study?

The study aimed to investigate the safety, tolerability, and efficacy of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.

Does selexipag improve hemodynamic parameters and have a favorable safety profile in children and young adults with idiopathic and heritable pulmonary arterial hypertension?

Population

11 patients (five children and six young adults) with idiopathic and heritable pulmonary arterial hypertension

Comparison

Selexipag as add-on therapy or transition from beraprost sodium or epoprostenol

Design

Retrospective cohort study

Authors

STShinichi Takatsuki TNTomotaka Nakayama YSYurika Shimizu

Discussion

Member takes

Overview

May support hemodynamic benefit of selexipag in pediatric PAH; hypothesis-generating and requires prospective trials before practice change.

Structured PICO

Does selexipag improve hemodynamic parameters and have a favorable safety profile in children and young adults with idiopathic and heritable pulmonary arterial hypertension?

Population

11 patients (5 children and 6 young adults) with idiopathic and heritable pulmonary arterial hypertension

Intervention

Selexipag as add-on therapy or as a transition from beraprost sodium or epoprostenol infusion therapy (median maintenance dose in children 80 μg/kg/day)

Outcome

Improvement in clinical variables from baseline, including hemodynamic parameters (mean pulmonary arterial pressure, pulmonary vascular resistance index, and cardiac index)surrogate

Selexipag demonstrated potential efficacy in improving hemodynamic parameters and a favorable safety profile in a small cohort of children and young adults with pulmonary arterial hypertension.

Cite This Study

Takatsuki et al. (2022) studied this question.

synapsesocial.com/papers/6a1ce2075b2142ad731dd301 https://doi.org/10.1017/s1047951122000415

View Full Paper

Ask AI

Bookmark